Timothy D. Matthews

Timothy D. Matthews

Auto-generated profile, based on publicly available information

Timothy D. Matthews

Birmingham Neuro-Ophthalmology Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in Ophthalmic Research
Verified
Journal Article
Open access
PDF file
CVColin J. Vize
Colin J. Vize
SKStella K. Kim
Stella K. Kim
TMTim Matthews
Tim Matthews
MMMarian Macsai
Marian Macsai
RMRyan Merrell
Ryan Merrell
GMGolnaz Moazami
Golnaz Moazami
Introduction: The Understanding New Interventions with GBM ThErapy (UNITE) study was designed to assess the effect of prophylaxis for ocular side effects (OSEs) in patients with glioblastoma receiving the antibody-drug conjugate (ADC) depatuxizumab mafodotin. UNITE (NCT03419403) was a phase 3b, open-label, randomized, exploratory study performed at 18 research sites in 5 countries. Methods: The study enrolled adult patients with epidermal growth factor receptor-amplified, histologically confirmed, newly diagnosed supratentorial glioblastoma or grade IV gliosarcoma, and a Karnofsky Performance Status ≥70, receiving depatuxizumab mafodotin. All patients were administered depatuxizumab mafodotin during concurrent radiotherapy and temozolomide and with adjuvant temozolomide. Ninety patients were to be randomized (1:1:1) to OSE prophylactic treatments with each depatuxizumab mafodotin infusion: (a) standard steroid eye drops, (b) standard steroid eye drops plus vasoconstrictor eye drops and cold compress, or (c) enhanced steroids plus vasoconstrictor eye drops and cold compress. A Corneal Epitheliopathy Adverse Event (CEAE) scale was devised to capture symptoms, grade OSEs (scale of 0–5), and inform ADC dose modifications. The primary endpoint was the frequency of a required change in OSE management due to inadequate control of OSEs, defined as decline from baseline in visual acuity (using logarithm of the minimum angle of resolution [LogMAR] scale) or a Grade ≥3 CEAE event, in the worst eye in the first 8 weeks of treatment; unless otherwise specified, the treatment period refers to both the chemoradiation and adjuvant phases. Results: The UNITE study was stopped early after interim analysis of separate phase III trial showed no difference in survival from depatuxizumab mafodotin. Forty patients were randomized (38 received depatuxizumab mafodotin). Overall, 23 patients experienced inadequate control of OSEs that required change in OSE management within 8 weeks of treatment, with 21 (70.0%) experiencing ≥+0.3 change on LogMAR scale in baseline-adjusted visual acuity and 12 reporting a grade ≥3 CEAE. There were no definitive differences among prophylactic treatments. Conclusions: The premature cessation of the study precludes definitive conclusions regarding the OSE prophylaxis strategies. No new clinically significant safety findings were noted. Despite these limitations, this study highlights the need for novel assessment tools to better understand and mitigate OSEs associated with ADCs.

20 January 2022 in Eye
Verified
Journal Article
Open access
PDF file
ACAntonio Calcagni
Antonio Calcagni
OHOlivia Howells
Olivia Howells
HBHannah Bartlett
Hannah Bartlett
ADAlastair K. O. Denniston
Alastair K. O. Denniston
JGJonathan M. Gibson
Jonathan M. Gibson
FEFrank Eperjesi
Frank Eperjesi
Background: Neovascular age‐related macular degeneration (nAMD) is a leading cause of blind registrations in the elderly. Unfortunately, it is difficult to detect the early stage of the disease, when treatment is more likely to be successful. Subjects with very early disease are likely to have abnormal macular function, even in the pre‐symptomatic stage. In this study, colour vision was evaluated to establish if subjects at high risk of developing nAMD can be identified, thus allowing earlier diagnosis and possible treatment. Methods: Colour contrast sensitivity (CCS) was evaluated over time in the fellow unaffected eye of subjects with unilateral nAMD. Participants were divided into Group 1 (182 participants) or Group 2 (15 participants) according to whether nAMD did not or did develop in the study period respectively and the two groups were compared. Results: CCS was increased (i.e. worse colour vision) compared with the age-matched reference range in a high proportion of fellow eyes in both Groups 1 and 2. Global mean CCS values did not show statistically significant differences between the two groups. However, there was a statistically significant difference between mean Group 1 CCS values and the last CCS value prior to nAMD diagnosis from Group 2 subjects. Conclusion: This study shows that in patients with unilateral nAMD, colour vision is frequently abnormal in the fellow unaffected eye. Abnormal CCS does not predict the development of nAMD within the 12 month period of the study and therefore it is not a viable screening tool for this pathology.

3 April 2023
Verified
Other
Open access
SSShruthi Sriramkumar
Shruthi Sriramkumar
TMTimothy D. Matthews
Timothy D. Matthews
AGAhmed H. Ghobashi
Ahmed H. Ghobashi
SMSamuel A. Miller
Samuel A. Miller
PVPamela S. VanderVere-Carozza
Pamela S. VanderVere-Carozza
HOHeather M. O'Hagan
Heather M. O'Hagan
RING1A monoubiquitinates phosphoH2AX at lysine 119 in response to cisplatin treatment

3 April 2023
Verified
Other
Open access
SSShruthi Sriramkumar
Shruthi Sriramkumar
TMTimothy D. Matthews
Timothy D. Matthews
AGAhmed H. Ghobashi
Ahmed H. Ghobashi
SMSamuel A. Miller
Samuel A. Miller
PVPamela S. VanderVere-Carozza
Pamela S. VanderVere-Carozza
HOHeather M. O'Hagan
Heather M. O'Hagan

3 April 2023
Verified
Other
Open access
SSShruthi Sriramkumar
Shruthi Sriramkumar
TMTimothy D. Matthews
Timothy D. Matthews
AGAhmed H. Ghobashi
Ahmed H. Ghobashi
SMSamuel A. Miller
Samuel A. Miller
PVPamela S. VanderVere-Carozza
Pamela S. VanderVere-Carozza
HOHeather M. O'Hagan
Heather M. O'Hagan

3 April 2023
Verified
Other
Open access
SSShruthi Sriramkumar
Shruthi Sriramkumar
TMTimothy D. Matthews
Timothy D. Matthews
AGAhmed H. Ghobashi
Ahmed H. Ghobashi
SMSamuel A. Miller
Samuel A. Miller
PVPamela S. VanderVere-Carozza
Pamela S. VanderVere-Carozza
HOHeather M. O'Hagan
Heather M. O'Hagan